Stem cell therapy for facioscapulohumeral muscular dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a new stem cell treatment (ULSC) for people with FSHD, a type of muscular dystrophy. It aims to see if the treatment is safe and if it can help improve arm strength and daily movement.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 15 years old.
- You need a confirmed diagnosis of FSHD type 1 or 2.
- You should be able to walk on your own and have a certain level of muscle weakness (Ricci score of 3 or higher).
- You must be willing to have MRI scans and follow the study schedule.
- If you could get pregnant or father a child, you must use two effective forms of birth control during the study and for 3 months after.
- Your arm strength on one side must be reduced but not too severely, as measured by a special test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at muscle MRI images and walking patterns (3D gait analysis) in people with FSHD. It helps researchers understand how the disease affects movement and muscle over time.
This study creates a patient-driven health and research platform for people with FSHD. It aims to collect information to better understand the condition and improve future research and care.
This study tests an experimental medicine called Del-brax (AOC 1020) for people with facioscapulohumeral muscular dystrophy (FSHD). The goal is to see if it can help improve muscle strength and slow the disease. You may be able to join if you have a confirmed FSHD diagnosis and can walk at least 10 meters on your own.
This study looks at how children with FSHD move and function over time. It uses walking tests and optional MRI scans to understand muscle changes. Your child's participation could help researchers learn more about FSHD progression in kids.
This study is testing a new medicine, SFL-0821, to see if it is safe and useful for people with FSHD. It may help if it works, but it is still experimental.
This study tests a new medicine called SAT-3247 to see if it can safely improve muscle strength in people with facioscapulohumeral muscular dystrophy (FSHD), a condition that causes muscle weakness, especially in the face, shoulders, and legs. Participating may help you and future patients by finding a treatment that could slow or reduce muscle loss.
Hear when a new FSHD - Facioscapulohumeral Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.